Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study.

ABSTRACT:

Background

The clinical impact of hypomagnesemia induced by necitumumab plus gemcitabine and cisplatin (GCN) as a second-line or later therapy is unclear.

Objective

We aimed to evaluate the clinical characteristics and survival impact of hypomagnesemia induced by this therapy.

Design

This was a sub-analysis of the retrospective multicenter NINJA study.

Methods

Among the 93 patients enrolled in the NINJA study, this subanalysis included 75 patients with baseline serum magnesium concentrations.

Results

The incidence of grade ⩾2 hypomagnesemia was 18.0% in the patients with normal baseline serum magnesium concentrations and 42.8% in those with low concentrations (p = 0.073). The discontinuation rates of GCN treatment owing to hypomagnesemia in each g

SUBMITTER: Tanzawa S 

PROVIDER: S-EPMC11829289 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature